Month: April 2025

STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q1 2025 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event. About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified biopharmaceutical...

IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented on April 26, 2025, at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. Individuals can access the webcast via the link on the company’s Investor Relations website, https://ir.cgoncology.com. An archive will be available following the completion of the call. About...

TORONTO, April 24, 2025 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 first quarter earnings conference call on Thursday, May 8, 2025 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on the Company’s website. About Cronos Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property...

CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present a late-breaking poster presentation on the RECOVER 12-month open label extension trial for brilaroxazine in schizophrenia at the 2025 American Society of Clinical Psychopharmacology (ASCP) annual meeting, taking place May 27-30, 2025, in Scottsdale, AZ. Details for the poster presentation can be found below: Title: Brilaroxazine’s Effects on Efficacy, Safety, Adherence, and Biomarkers in the Phase 3 Recover 12-Month...

More than a dozen AON leaders to speak on panels focused on advocacy, innovation and access in independent community oncology FORT MYERS, Fla., April 24, 2025 (GLOBE NEWSWIRE) — American Oncology Network (AON), one of the nation’s fastest-growing community oncology networks, today announced that it will participate in 14 speaking sessions at the 2025 Community Oncology Alliance (COA) Annual Conference. The event, themed Empower & Advocate: Independent Community Oncology, will take place April 29-30 in Orlando, Florida.“At AON, we’re committed to supporting local practices because they bring immense value to patients and communities,” said Stephen “Fred” Divers, MD, AON’s chief medical officer, medical oncologist at Genesis Cancer and Blood Institute, and conference co-chair. “The conference theme of empowerment and advocacy...

~ Strong start to the year with 1Q25 financial results ~~ Reiterating 2025 sales and adjusted operating income outlook; raising adjusted EPS outlook ~ PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended March 28, 2025.   First Quarter 2025 Highlights (compared to First Quarter 2024, except as noted)Sales increased 7% to $437 million, with organic growth of 6%. GAAP operating income increased $11 million to $50 million, an increase of 28%. Non-GAAP adjusted operating income increased $9 million to $71 million, an increase of 14%. GAAP income (loss) from continuing operations decreased $43 million to a $22 million loss, primarily from debt conversion inducement expense related to the exchange of 2028 convertible notes. Non-GAAP adjusted net...

The MCPF1412 power module with integrated I2C and PMBus® interfaces for flexible configuration and monitoring CHANDLER, Ariz., April 24, 2025 (GLOBE NEWSWIRE) — AI at the edge is driving increased integration and power consumption, requiring advanced power management solutions for industrial automation and data center applications. Microchip Technology (Nasdaq: MCHP) today announces the MCPF1412, a highly efficient and fully integrated point-of-load 12A power module with a 16V VIN buck converter and support for I2C and PMBus® interfaces. The MCPF1412 power module is designed to deliver superior performance and reliability, ensuring efficient power conversion and reduced energy loss. Its compact form factor of 5.8 mm × 4.9 mm × 1.6 mm and innovative Land Grid Array (LDA) package significantly reduce the required board space by over...

>8,500 samples and 100 million cells of high resolution and fully annotated spatial proteomics data available MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Enable Medicine, a real-world data company providing AI-ready patient, cellular and molecular data, today announced a groundbreaking collaboration to deliver the largest commercially available single-cell spatial proteomics atlas to the research and clinical community. Enable Medicine’s Pan-Cancer Atlas is a unique multi-modal dataset built using Akoya’s PhenoCycler®-Fusion (PCF) platform and includes the PhenoCode™ Discovery IO60 panel as its foundational data. The Enable Atlas comprises over 100 million single cells, spanning 8,500+ samples and 15+ cancer types, with rich cellular features,...

Now embedded on over 41.9 million consumer devices with 16.5 million monthly active users Delivering 8 billion+ API calls and 27.9 million GeoZone triggers so far this yearNEW YORK, April 24, 2025 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV), the company reinventing retail through real-time AI-driven consumer engagement, today announced its financial results for the year ended December 31, 2024. As expected, revenue for 2024 was immaterial, with the company focused on laying the strategic foundation for commercial scale. Rezolve believes that scale has now arrived with the opening months of 2025 delivering explosive growth in platform usage and measurable impact. Rezolve Ai is now live with more than 50 enterprise customers, including Liverpool, Phoenix Suns, BJs Wholesale, Ace Hardware, Discount Tire, RS Components, KFC and...

(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer patient Treatment well-tolerated and patient remains on study with stable disease elsewhere Sustained clinical response supports Bria-OTS personalized, off-the-shelf immunotherapy approach in Phase 1/2a metastatic breast cancer studyPHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months after initial treatment in the ongoing Phase 1/2 Bria-OTS study. The latest data at four...